Peter Novak

Peter Novak

Auto-generated profile, based on publicly available information

Peter Novak

Affiliations Department of Neurology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, Harvard University, Boston, Massachusetts, United States of America

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
PNPeter Novak
Peter Novak
SMShibani Mukerji
Shibani Mukerji
HAHaitham S. Alabsi
Haitham S. Alabsi
DSDavid Systrom
David Systrom
SMSadie P. Marciano
Sadie P. Marciano
DPDavid M. Pilgrim
David M. Pilgrim

25 April 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PNPeter Novak
Peter Novak
DMDaniela Arantxa Pimentel Maldonado
Daniela Arantxa Pimentel Maldonado
VNVera Novak
Vera Novak
Parkinson disease (PD) is associated with cognitive impairment. We aimed to determine the effects of intranasal insulin (INI) on cognition and motor performance in PD. This was a proof of concept, randomized, double-blinded, placebo-controlled trial evaluating the effects of 40 international units (IU) of insulin or saline once daily for four weeks on cognitive and functional performance. Of 16 subjects enrolled, eight in the INI group and six in the placebo group completed verbal fluency (FAS), Unified Parkinson Disease Scale (UPDRS), and modified Hoehn and Yahr scale (HY, PD severity) at baseline and post-treatment and were included in the analyses. After treatment, the INI group had a better total FAS score (p = 0.02) (41 ± 8.2 vs. 30.8 ± 7.1, mean ±SD, p = 0.02) compared to the placebo group. The INI group also had improved HY (p = 0.04) and UPDRS-Motor (Part III) (p = 0.02) scores when compared to baseline. One INI treated patient with multiple system atrophy (MSA) remained stable and did not show disease progression. The placebo group had no change. INI administration was well tolerated and there were no hypoglycemic episodes or serious study related adverse events or medications interactions. INI is safe in PD and MSA patients and may provide clinically relevant functional improvement. Larger studies are warranted to determine the INI effect in treatment of cognitive and motor impairment in Parkinson disease. Trial Registration: ClinicalTrial.gov NCT02064166.

26 September 2017 in Clinical Autonomic Research
Verified
Journal Article
Closed access
PDF file
PNPeter Novak
Peter Novak

24 August 2016 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
PNPeter Novak
Peter Novak
Purpose: Electrochemical skin conductance (ESC) using reverse iontophoresis and chronoamperometry has been used to evaluate abnormal function of small fibers. How ESC correlates with loss of small fibers in skin is unclear. Methods: This was a prospective, blinded study. The primary outcome measure was the correlation between ESC at the feet and results of skin biopsies including epidermal nerve fiber density (ENFD) and sweat gland nerve fiber density (SGNFD) at the distal leg. ESC, ENFD and SGNFD data were normalized by adjusting for weight. The secondary outcome measures were the correlation between ESC and the following variables: quantitative sudomotor axon reflex test (QSART) and symptom scales (neuropathy, pain and autonomic). Results: 81 patients ((mean±sd): age=53.3±17.3, men/women=25/56 were enrolled in the study. ESC was reduced in subjects with abnormally low ENFD (ENFD normal/abnormal, ESC = 1.17±0.27/0.87±0.34 µSiemens/kg, p<0.0008) and abnormally low SGNFD (SGNFD normal/abnormal ESC=1.09±0.34/,0.78±0.3 µSiemens/kg,p<0.0003). ESC correlated with ENFD (ρ=0.73, p=0.0001) and SGNFD (ρ=0.64, p=0.0001). ESC did not correlate with symptom scales. Conclusion: ESC is diminished in subjects who have a reduced number of small fibers in the skin and the ESC reduction is proportional to ENFD and SGNFD. ESC can be useful in detecting loss of small nerve fibers.

16 February 2016 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PNPeter Novak
Peter Novak
Objective: Orthostatic dizziness without orthostatic hypotension is common but underlying pathophysiology is poorly understood. This study describes orthostatic cerebral hypoperfusion syndrome (OCHOS). OCHOS is defined by: 1) Abnormal orthostatic drop of cerebral blood flow velocity (CBFv) during the tilt test; and 2) Absence of orthostatic hypotension, arrhythmia, vascular abnormalities, or other causes of abnormal orthostatic CBFv. Methods: This retrospective study included patients referred for evaluation of unexplained orthostatic dizziness. Patients underwent standardized autonomic testing including 10 minutes of tilt test. The following signals were monitored: heart rate, end tidal CO2, blood pressure and CBFv from the middle cerebral artery using transcranial Doppler. Patients were screened for OCHOS. Patients which fulfilled the OCHOS criteria were compared to age and gender matched controls. Results: From 1279 screened patients, 102 patients (60/42 women/men, age 51.1±14.9, range 19-84 years) fulfilled criteria of OCHOS. There was no difference in baseline supine hemodynamic variables between OCHOS and the control group. During the tilt, mean CBFv decreased 24.1±8.2% in OCHOS versus 4.2±5.6% in controls (p<0.0001) without orthostatic hypotension in both groups. Supine mean blood pressure (OCHOS/controls, 90.5±10.6/91.1±9.4 mmHg, p=0.62) remained unchanged during the tilt (90.4±9.7/92.1±9.6 mmHg, p=0.2). End tidal CO2 and heart rate responses to the tilt were normal and equal in both groups. Conclusion: OCHOS is a novel syndrome of low orthostatic CBFv. Two main pathophysiological mechanisms are proposed including active cerebral vasoconstriction and passive increase of peripheral venous compliance. OCHOS may be a common cause of orthostatic dizziness.

12 July 2016 in Neuroscience Journal
Verified
Journal Article
Open access
PDF file
PNPeter Novak
Peter Novak
Objective. The head-up tilt test is widely used for evaluation of orthostatic intolerance. Although orthostatic symptoms usually reflect cerebral hypoperfusion, the cerebral blood flow velocity (CBFv) profile in orthostatic syndromes is not well described. This study evaluated CBFv and cardiovascular patterns associated with the tilt test in common orthostatic syndromes. Methods. This retrospective study analyzed the tilt test of patients with history of orthostatic intolerance. The following signals were recorded: ECG, blood pressure, CBFv using transcranial Doppler, respiratory signals, and end tidal CO2. Results. Data from 744 patients were analyzed. Characteristic pattern associated with a particular orthostatic syndrome can be grouped into abnormalities predominantly affecting blood pressure (orthostatic hypotension, orthostatic hypertension syndrome, vasomotor oscillations, and neurally mediated syncope—cardioinhibitory, vasodepressor, and mixed), cerebral blood flow (orthostatic hypoperfusion syndrome, primary cerebral autoregulatory failure), and heart rate (tachycardia syndromes: postural tachycardia syndrome, paroxysmal sinus tachycardia, and inappropriate sinus tachycardia). Psychogenic pseudosyncope is associated with stable CBFv. Conclusions. The tilt test is useful add-on in diagnosis of several orthostatic syndromes. However diagnostic criteria for several syndromes had to be modified to allow unambiguous pattern classification. CBFv monitoring in addition to blood pressure and heart rate may increase diagnostic yield of the tilt test.